Winona makes the relationship between a prescription and continuing messages central to its menopause service. That can be attractive to someone who wants written communication, but it creates a different experience from a scheduled video consultation. The public records also require care when separating approved medicines from compounded creams.
We reviewed Winona’s current FAQ and two estrogen product pages on September 28, 2026. We did not submit a medical intake or test the service. This review follows the practical path from eligibility and communication to the medicine description, subscription charge and follow-up questions.
A Winona product price includes a particular service and prescription format; neither the bioidentical label nor portal access establishes individual suitability.
A message-based service with a defined entry boundary
The Winona FAQ says its HRT service is for women aged 35–59 and lists the states and territory it currently serves. That is the company’s enrollment scope, not a clinical rule establishing who should use estrogen. A reader outside that age range should not translate a platform restriction into a conclusion that care elsewhere is inappropriate.
Winona says a state-licensed doctor reviews the submitted history and assigns treatment when appropriate. It does not offer physician phone or video calls. Someone who wants a live discussion should compare that arrangement with Gennev’s video-visit model, while checking current appointment availability separately.
The approval statement changes with the product
The same FAQ initially describes its bioidentical options broadly as compounded, but later distinguishes FDA-approved tablets, progesterone capsules and patches from compounded creams. The estrogen patch page also describes that patch as FDA-approved. These product-specific statements are more informative than treating the whole brand as one regulatory category.
The combined body cream page names estradiol, estriol and progesterone. Its ingredient list does not establish approval of the finished preparation. FDA’s compounding explanation says compounded drugs do not undergo the agency’s premarket evaluation for safety, effectiveness and quality. Obtain the exact dispensed product’s identity rather than resolving the broad FAQ wording by assumption.
A combination cream needs a specific clinical explanation
The cream page promotes convenience and uterine protection from its combined ingredients. A reader cannot verify the adequacy of a particular protection plan from the presence of progesterone in a marketing description. The relevant discussion is why that formulation, route and follow-up have been selected for that person.
FDA’s menopause information explains the endometrial risk associated with estrogen in someone with a uterus and the role of adding a progestin. It also states that estriol-containing drugs are not FDA-approved. Our estrogen and progesterone guide helps separate the general clinical question from a claim about one compounded product. This review supplies no regimen or substitute prescription.
Published starting prices are different prescription records
Winona displays the patch from $149 per month and the estrogen/progesterone body cream from $89 per month on their respective product pages. Both describe included physician access and standard shipping. These are starting prices for different preparations, not two interchangeable ways to buy an identical treatment plan.
The FAQ says the total depends on whether one or several products are prescribed and that Winona does not bill insurance directly. A possible reimbursement receipt is not a coverage commitment. Ask for the full selected charge, supply period and any additional medicine before comparing the offer with Joi’s separately billed care and prescriptions. Neither headline alone gives an annual patient-specific total.
The refill clock runs ahead of the stated supply
The FAQ’s billing section says a 30-day supply is processed every 28 days and a 90-day supply every 84 days. Those intervals matter when reading a monthly display. They should not be silently replaced by calendar-month or calendar-quarter assumptions.
The same source describes a 24-hour processing window for order cancellation and refund, followed by a point after which an order cannot be cancelled, refunded or returned. Cancelling future subscriptions is therefore different from reversing an order already in process. It also identifies exceptions to automatic refills for vaginal estrogen cream and arousal cream. Confirm the rule attached to the actual prescription; this review did not enter an account or test cancellation.
Access to a portal is not an immediate medical response
Winona advertises round-the-clock access to messaging, while its FAQ says doctors typically reply within 24–48 hours and sometimes take longer. Those statements can coexist: the ability to send a message does not mean a clinician is continuously reviewing it. The company separately describes customer support for nonmedical concerns.
Before enrolling, clarify the route for symptoms that require examination or timely local care. NHS guidance says bleeding after menopause should be checked even when it occurs once or is slight; that clinical message does not imply Winona can perform the necessary examination remotely. Ordinary portal messaging should not delay urgent care. Keep the local clinician’s role clear alongside the remote prescriber’s responsibilities.
Judge the plan by its named medicine and workable follow-up
Winona’s record supports a real online menopause prescribing service with several formats and published commercial terms. It does not support a promise that a particular cream is appropriate, that every advertised symptom will improve, or that an individual’s costs stop at one starting figure. Broad symptom lists and patient stories are not comparative trial results.
Use patch versus pill to prepare route questions and questions before starting estrogen to organize the consultation. The decision becomes clearer when the record contains a named medication, the reason for that route, a full billing schedule and an agreed route for problems. A convenient written-care format should serve those needs rather than obscure them.
Sources & reading
Source check dates appear with each record below. Provider pages describe their own services; they do not establish clinical superiority.
- Winona: care, prescribing, payment and refill FAQ ↗Provider FAQ; product-category wording differs internally, state/age restrictions and messaging limits retained · Checked 2026-09-28
- Winona: estrogen patch product record ↗Provider product page; starting price and FDA-approval statement attributed, no supplied medicine inspected · Checked 2026-09-28
- Winona: estrogen body cream with progesterone ↗Provider compounded-combination product record; marketing protection claims are not independently established · Checked 2026-09-28
- FDA: Understanding the Risks of Compounded Drugs ↗Federal regulatory explanation of compounded drug approval limits; no inference about a particular pharmacy inspection · Checked 2026-09-28
- FDA: Menopause ↗Current federal patient guidance; individualized benefits/risks and prevention limits, no class-wide labeling-change inference · Checked 2026-09-28
- NHS: Postmenopausal bleeding ↗UK public clinical guidance; need for assessment only, UK referral timing not transferred to US services · Checked 2026-09-28